8-K 1 d175421d8k.htm 8-K 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 8-K

 

 

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 19, 2016

 

 

Corcept Therapeutics Incorporated

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-50679   77-0487658

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

149 Commonwealth Drive

Menlo Park, CA 94025

(Address of principal executive offices, with zip code)

(650) 327-3270

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 5.07 Submission of Matters to a Vote of Security Holders

On May 19, 2016, we held our annual meeting of stockholders to consider and vote on proposals: 1) to elect seven directors to hold office until our 2017 annual meeting of stockholders and until their successors are elected and qualified, and 2) to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.

A total of 109,710,939 shares of Corcept common stock held by stockholders of record at the close of business on April 8, 2016 were entitled to vote at the annual meeting. The total number of shares voted at the annual meeting was 103,229,513. The voting on the two matters is set forth below:

Proposal 1 – Election of Directors. The following directors were elected to serve until our 2017 annual meeting of stockholders and until their successors are elected.

 

Director:    For      Withheld      Broker Non-
Votes
 

G. Leonard Baker, Jr.

     71,279,606         3,320,003         28,629,904   

Joseph K. Belanoff, M.D.

     74,007,363         592,246         28,629,904   

Daniel M. Bradbury

     57,529,377         17,070,232         28,629,904   

Patrick G. Enright

     73,929,155         670,454         28,629,904   

David L. Mahoney

     73,887,755         711,854         28,629,904   

Daniel N. Swisher, Jr.

     59,574,984         15,024,625         28,629,904   

James N. Wilson

     65,747,905         8,851,704         28,629,904   

Proposal 2 – To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016.

 

For

     102,079,492   

Against

     1,142,934   

Abstain

     7,087   

Broker Non-Votes

     N/A   


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    CORCEPT THERAPEUTICS INCORPORATED
Date: May 19, 2016     By:  

/s/ G. Charles Robb

      G. Charles Robb
      Chief Financial Officer and Secretary